Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Anja Richter

Gerhard Siemeister

Hans Briem

Anne Mengel

Ursula Mönning

Simon Holton

Marion Hitchcock

Cornelia Preuβe

Wilhelm Bone

Amaury Ernesto Fernandez-Montalvan

Jens Schröder

Philip Lienau

Andrea Hägebarth

Ulrich Klar

William Johnston Scott

Knut Eis

Lars Bärfacker

Ludwig Zorn

Kai Thede

Mark Jean Gnoth

Detlev Sülzle

Ningshu Liu

Stefan Golz

Georg Kettschau

Kirstin Petersen

Christian Stegmann

Lars Wortmann

Dirk Schneider

Florian Puehler

Stefan Prechtl

Eckhard Bender

Franziska Siegel

Manfred Möwes

Vera Pütter

Cornelia Preusse

Daniel Basting

Amaury Ernesto Fernández-Montalván

Florian Püehler

Lars BÄRFACKER

The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: Lrepresents an optionally substituted methylene or ethylene group; Lrepresents &#x2014;N(H)&#x2014;C(&#x2550;O)&#x2014; or &#x2014;C(&#x2550;O)&#x2014;N(H)&#x2014;; Rrepresents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or &#x2014;N(R7)(Ci-C6-alkyl) group; Rrepresents an optionally substituted 5- or 6-membered heteroaryl group; Rrepresents an optionally substituted phenyl group. 

Compounds

Compounds of formula (I), and their use as pharmaceuticals. 

Substituted benzylpyrazoles

Compounds of formula (I), which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

Heteroaryl substituted pyrazoles

Compounds of formula (I), processes for their preparation and their use as pharmaceuticals. 

Compounds of formula (I) and their use as pharmaceutical. 

The present invention relates to substituted pyrrolopyrimidinylamino-benzothiazolone compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors

Growing community of inventors

Berlin, Germany

Anja Richter